Literature DB >> 35085501

Beyond anti-VEGF: can faricimab reduce treatment burden for retinal disease?

Mark A Chia1, Pearse A Keane2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35085501     DOI: 10.1016/S0140-6736(22)00105-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  2 in total

1.  Eligibility for faricimab in a real-world neovascular age-related macular degeneration population: a cross-sectional study.

Authors:  Iréne Jern; Sara Forsell; Helena Norberg
Journal:  BMJ Open       Date:  2022-09-12       Impact factor: 3.006

2.  Transition from Laser to Intravitreal Injections for Diabetic Retinopathy: Hospital Utilization and Costs from an Extended Healthcare Perspective.

Authors:  Silvia Nanjala Walekhwa Hertzberg; Øystein K Jørstad; Beáta Éva Petrovski; Ragnheidur Bragadottir; Leif Arthur Steffensen; Morten Carstens Moe; Emily A Burger; Goran Petrovski
Journal:  Int J Environ Res Public Health       Date:  2022-10-02       Impact factor: 4.614

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.